Spectral Medical Provides Tigris Trial Update
Spectral Medical Inc. updates on Tigris trial, a Phase 3 study for PMX in treating endotoxemia and septic shock, with 81 patients enrolled. Strong enrollment and screening activity continue, nearing the interim target of 90 patients. Preliminary mortality data exceeds expectations. Spectral also completed the EDEN study, providing valuable data on septic shock and endotoxin activity.
Reference News
Spectral Medical Inc. updates on Tigris trial, a Phase 3 study for PMX in treating endotoxemia and septic shock, with 81 patients enrolled. Strong enrollment and screening activity continue, nearing the interim target of 90 patients. Preliminary mortality data exceeds expectations. Spectral also completed the EDEN study, providing valuable data on septic shock and endotoxin activity.
Spectral Medical Inc. updates on Phase 3 Tigris trial for septic shock treatment, enrolling patient 82 and nearing interim target of 90. Screening exceeds 100 patients weekly. Dr. John Kellum and CEO Chris Seto express optimism for 2024, highlighting progress and preliminary mortality data exceeding expectations.